Supplies of lateral flow tests may need to be “constrained” amid rising demand, Sajid Javid says.View More Covid-19: Calls to give NHS staff priority access to lateral flow tests
“The government is following the test, track, treat and vaccinate strategy whilst preparing the overall health infrastructure to tackle any possible surge in COVID cases,” said Dr VK Paul, Health Official, Niti Aayog.
Lav Agarwal, Joint Secretary, Union Health Ministry highlighted that the COVID numbers are surging across the nation with the average daily cases for the past one week rising to 8,009. The active cases now stand at 82,402 with Kerala ( 25.66%) and Maharashtra (21.33%) contributing the maximum number of active cases.
Speaking about the surge in cases witnessed in the country, Dr VK Paul, Health Official, Niti Aayog said, “There is an uptick in the number of COVID cases as can be seen by the number of cases recorded in the last 24 hours. Delhi, Maharashtra or Mumbai in particular, Punjab, Haryana, Jharkhand, Chhattisgarh among many states are showing a rise in cases and an
The spike in reported cases comes as frustration grows over a lack of available lateral flow tests.View More Covid: Daily UK case numbers hit record of 183,037
The group had introduced Avifavir in the market back in June 2020 with the help of Russian Direct Investment Fund (RDIF), becoming the first pharmaceutical group to release a direct antiviral for COVID-19 treatment. The product’s efficacy was confirmed with a full-scale clinical trial in Russia involving 460 COVID patients. The antiviral drug is currently being supplied to more than 15 countries around the world as part of the COVID treatment.
A meta-analysis of 23 COVID-19 treatment studies for favipiravir demonstrated a 47 percent improvement when Favipiravir is used in early treatment of coronavirus. The clinical trials of Avifavir have demonstrated the presence of anti-COVID properties, such as alleviating symptoms and cutting the duration of the disease by half compared to the standard therapy.
The clinical trials conducted for the medicinal drug Avifavir also proved that the virus is incapable of
Gillian Keegan’s comments come as England reports another record 117,093 Covid cases.View More Covid: Enjoy new year but be cautious, care minister says
“It is likely that India will see a period of explosive growth in daily cases and that the intense growth phase will be relatively short,” Paul Kattuman, professor at the Judge Business School at the University of Cambridge which has developed a Covid-19 India tracker, wrote in an email.
“New infections will begin to rise in a few days, possibly within this week,” he said, adding that it was hard to predict how high the daily cases could go.
Kattuman and his team of researchers, developers of the India Covid tracker, are seeing a sharp rise in infection rates across India.
The tracker spotlighted six states as a “significant concern” in a December 24 note, with adjusted growth rate of new cases exceeding 5%. This had expanded to 11 Indian states by December 26, according to the tracker, which corrects for “day of the week effects” and other variations.
India, which has confirmed 34.8 million infections and 480,290 deaths so far, is already gearing up to